By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Bionomics Limited 

31 Dalgleish Street

Thebarton  South Australia  5031  Australia
Phone: 618-8354-6100 Fax: 618-8354-6199




Nanogen, Inc.  Epilepsy diagnostic product development

Genmab A/S  Anti-angiogenesis therapeutic antibody development

Univ. of Melbourne, Women's & Children's Hospital 

Brigham and Women's Hospital 

Howard Florey Institute 

Company News
Bionomics Limited (BNO.AX) Reports Positive Data From Phase 1 Multiple Ascending Dose Trial Of BNC210 For Anxiety And Depression 9/16/2015 5:56:28 AM
Bionomics Limited (BNO.AX) Release: Successful BNC101 IND Submission Paves Way For Development Of Promising Cancer Stem Cell Drug Candidate 8/31/2015 6:39:02 AM
Bionomics Limited (BNO.AX) Files Patent For Use Of BNC105 In Combination With PD-1 And CTLA-4 Immuno-Oncology Antibodies 6/15/2015 6:17:32 AM
Bionomics Limited (BNO.AX) Initiates Phase II Clinical Trial Of BNC210 For Treatment Of Anxiety 4/20/2015 8:36:39 AM
Bionomics Limited (BNO.AX) Showcases Oncology Drug Development Programs At 2015 American Association for Cancer Research Annual Meeting 4/17/2015 6:48:33 AM
Bionomics Limited (BNO.AX) Release: BNC105 Biomarker Data To Be Presented At Asian Oncology Conference 4/10/2015 11:11:47 AM
Bionomics Limited (BNO.AX) Begins Trading On OTCQX Marketplace 3/2/2015 7:42:13 AM
Bionomics Limited (BNO.AX) Release: New BNC105 Biomarker Data To Be Presented At US Cancer Conference 2/27/2015 9:54:03 AM
Bionomics Limited (BNO.AX) Begins Phase 1b Study With Anxiety Drug Bnc210 2/2/2015 9:22:23 AM
Bionomics Limited (BNO.AX) Release: BNC101 Data To Be Presented At European Cancer Conference 11/21/2014 2:51:21 PM